156 results on '"Schumock, Glen T."'
Search Results
2. Adherence and Persistence of HIV Pre‐Exposure Prophylaxis use in the United States
3. Trends of nonoccupational postexposure prophylaxis in the United States
4. Evaluating the use of methods to mitigate bias from non‐transient medications in the case‐crossover design: A systematic review
5. Anatomy of Risk Evaluation and Mitigation Strategies (REMS)
6. Adherence to HIV Pre-Exposure Prophylaxis Testing Guidelines in the United States
7. National trends in prescription drug expenditures and projections for 2023
8. National trends in prescription drug expenditures and projections for 2022
9. Risk of fall‐related injury and all‐cause hospitalization of select concomitant central nervous system medication prescribing in older adult persistent opioid users: A case‐time‐control analysis
10. National trends in prescription drug expenditures and projections for 2021
11. Risk of cardiac events with azithromycin—A prediction model
12. Comparison of Cardiac Events Associated With Azithromycin vs Amoxicillin
13. National trends in prescription drug expenditures and projections for 2020
14. Prevalence of Cardiac Risk Factors in Patients Prescribed Azithromycin before and after the 2012 FDA Warning on the Risk of Potentially Fatal Heart Rhythms
15. Estimating the Impact of Food and Drug Administration’s Unapproved Drug Initiative on Drug Prices and Sales
16. Adherence and Persistence with DPP-4 Inhibitors Versus Pioglitazone in Type 2 Diabetes Patients with Chronic Kidney Disease: A Retrospective Claims Database Analysis
17. Sodium‐glucose co‐transporter 2 inhibitors and the risk of fractures: A propensity score‐matched cohort study
18. Impact of multimorbidity subgroups on the health care use of early pediatric cancer survivors
19. National trends in prescription drug expenditures and projections for 2019
20. Estimating the Impact of Food and Drug Administration’s Unapproved Drug Initiative on Drug Prices and Sales
21. Multimorbidity and healthcare utilization among early survivors of pediatric cancer
22. Increased risk of mycotic infections associated with sodium–glucose co‐transporter 2 inhibitors: a prescription sequence symmetry analysis
23. Spending on Antineoplastic Agents in the United States, 2011 to 2016
24. Risk of amputations associated with SGLT2 inhibitors compared to DPP-4 inhibitors: A propensity-matched cohort study
25. National trends in prescription drug expenditures and projections for 2018
26. Risk of Diabetes Hospitalization or Diabetes Drug Intensification in Patients With Depression and Diabetes Using Second-Generation Antipsychotics Compared to Other Depression Therapies
27. The impact of depression medications on oral antidiabetic drug adherence in patients with diabetes and depression
28. Tumor necrosis factor-alpha inhibitors and risk of non-Hodgkin lymphoma in a cohort of adults with rheumatologic conditions
29. Pharmacy staffing, workload, and productivity benchmarks in state psychiatric hospitals
30. Risk of Serious Bacterial Infection Associated With Tumor Necrosis Factor–Alpha Inhibitors in Children and Young Adults With Inflammatory Bowel Disease
31. Predicting Acute Exacerbations in Chronic Obstructive Pulmonary Disease
32. The Relationship Between Oseltamivir and Suicide in Pediatric Patients
33. Nine years of comparative effectiveness research education and training: initiative supported by the PhRMA Foundation
34. Comparative effectiveness and patient-centered outcomes research: enhancing uptake and use by patients, clinicians and payers
35. Lifestyle-related attitudes: do they explain self-rated health and life-satisfaction?
36. Antibiotic Expenditures by Medication, Class, and Healthcare Setting in the United States, 2010–2015
37. National trends in prescription drug expenditures and projections for 2017
38. Influence of drug class and healthcare setting on systemic antifungal expenditures in the United States, 2005–15
39. Risk of Cardiovascular and Cerebrovascular Events in COPD Patients Treated With Long-Acting β2-Agonist Combined With a Long-Acting Muscarinic or Inhaled Corticosteroid
40. Risk of serious bacterial infection associated with tumour necrosis factor-alpha inhibitors in children with juvenile idiopathic arthritis
41. Comparative Effectiveness of Long-Acting Beta2-Agonist Combined with a Long-Acting Muscarinic Antagonist or Inhaled Corticosteroid in Chronic Obstructive Pulmonary Disease
42. Spending on Hepatitis C Antivirals in the United States, 2009-2015
43. The Rising Cost of Prescription Drugs: Causes and Solutions
44. Use of Tumor Necrosis Factor-Alpha Inhibitors in Children and Young Adults With Juvenile Idiopathic Arthritis or Rheumatoid Arthritis
45. Measuring the Value of Pharmaceuticals in the US Health System
46. Top-down Versus Step-up Prescribing Strategies for Tumor Necrosis Factor Alpha Inhibitors in Children and Young Adults with Inflammatory Bowel Disease
47. National trends in prescription drug expenditures and projections for 2016
48. Risk of Non-Hodgkin Lymphoma Following Treatment of Inflammatory Conditions with Tumor Necrosis Factor-Alpha Inhibitors
49. Tumor Necrosis Factor-Alpha Inhibitor Medications for Inflammatory Conditions and Incidence of Multiple Myeloma
50. Influenza Antiviral Expenditures and Outpatient Prescriptions in the United States, 2003-2012
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.